Last kr716.00 DKK
Change Today -17.00 / -2.32%
Volume 11.7K
ALKB On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
OTC US
As of 11:03 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (ALKB) Snapshot

Open
kr737.00
Previous Close
kr733.00
Day High
kr738.00
Day Low
kr690.00
52 Week High
06/20/14 - kr870.00
52 Week Low
10/10/13 - kr470.00
Market Cap
7.3B
Average Volume 10 Days
6.2K
EPS TTM
kr19.46
Shares Outstanding
9.2M
EX-Date
03/13/14
P/E TM
36.8x
Dividend
kr5.00
Dividend Yield
0.70%
Current Stock Chart for ALK-ABELLO A/S (ALKB)

Related News

No related news articles were found.

alk-abello a/s (ALKB) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (ALKB) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies. The company offers allergy immunotherapy products as injections, sublingual drops, and tablets. It provides GRAZAX, a tablet-based vaccine for grass pollen allergy; SLITone, a droplet-based allergy vaccine for daily administration through a single-dose container; and Alutard SQ, a product for subcutaneous allergy vaccination. The company’s products also include JEXT, an adrenaline auto-injector used to treat acute allergic reactions; and AVANZ, an injection based immunotherapy product. Its products in pipeline comprise Grass AIT, which has completed Phase III clinical trial for the treatment of grass allergic rhinoconjunctivitis (ARC); GRAZAX that is in Phase III clinical trial for asthma prevention; Ragweed AIT, a Phase III clinical trial product for ragweed ARC; HDM AIT for the treatment of house dust mite asthma and rhinitis; and Tree AIT, a Phase II clinical trial product for the treatment of tree ARC. In addition, the company focuses on developing AIT products against Japanese cedar pollen allergy; and products for cat allergies, as well as manufactures allergen extracts for allergy testing, such as skin-prick tests. The company provides its products through distributors worldwide. ALK-Abelló A/S has partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,791 Employees
Last Reported Date: 08/13/14
Founded in 1923

alk-abello a/s (ALKB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (ALKB) Key Developments

ALK-Abelló A/S Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-05-2014

ALK-Abelló A/S Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-05-2014 . Venue: London, United Kingdom. Speakers: Per Plotnikof, Director of IR & Strategic Planning.

ALK-Abelló A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 through Sep-11-2014

ALK-Abelló A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 through Sep-11-2014. Venue: The Grand Hyatt Hotel, New York, New York, United States. Presentation Date & Speakers: Sep-09-2014, Jens Bager, Chief Executive Officer, President and Member of the Board of Management.

ALK-Abelló A/S Reports Unaudited Earnings Results for the Second Quarter and Six Months of 2014; Revises Earnings Guidance for Fiscal 2014

ALK-Abelló A/S reported unaudited earnings results for the second quarter and six months of 2014. Revenue grew by 17% to DKK 615 million against DKK 532 a year ago. Growth was driven by a 143% increase in revenue from SLIT-tablets, mainly due to milestone payments and reimbursements from partners. EBITDA before special items grew to DKK 109 million against a loss of DKK 7 million a year ago as a result of higher revenue and lower R&D expenses. Cash flow from operations was an inflow of DKK 179 million against an outflow of DKK 5 million a year ago. The company has reported that net profit for the second quarter ended June 30, 2014 was DKK 31 million, or DKK 3.13 per diluted share, compared to a net loss of DKK 30 million, or DKK 3.08 loss per diluted share, for the same quarter ended June 30, 2013. First half revenue hence grew 15% to DKK 1,299 million against DKK 1,142 million a year ago. EBITDA before special items was DKK 320 million against DKK 94 million a year ago. The company Net profit for the six months ended June 30, 2014 was DKK 139 million, or DKK 14.04 per diluted share, compared to DKK 12 million, or DKK 1.23 per diluted share, for the same period ended June 30, 2013. For fiscal 2014, revenue is still expected to equal approximately DKK 2.4 billion. EBITDA is now expected at approximately DKK 450 million before special items, (previously, EBITDA was expected at approximately DKK 425 before special items and future income from product supply and sales royalties in North America). The outlook now includes an estimated income from product supply and sales royalties from SLIT-tablets in North America.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKB:DC kr716.00 DKK -17.00

ALKB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 24.75 GBp 0.00
DBV Technologies SA €25.57 EUR +0.57
Merck & Co Inc $60.49 USD +0.18
Sanofi €88.76 EUR +0.30
Stallergenes SA €52.00 EUR -1.05
View Industry Companies
 

Industry Analysis

ALKB

Industry Average

Valuation ALKB Industry Range
Price/Earnings 35.2x
Price/Sales 2.7x
Price/Book 2.8x
Price/Cash Flow 32.9x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.